Header
Ihr Suchergebnis
Sie recherchieren derzeit unangemeldet.Melden Sie sich an (Login) um den vollen Funktionsumfang der Datenbank nutzen zu können.
Sie suchen in allen Bereichen nach dem Autor Deutschle G.
In der Rubrik Zeitschriften haben wir 1 Beitrag für Sie gefunden
-
MerkenReady-to-use containers for sterile injectables will reduce the Total Cost of Ownership
Rubrik: Praxis
(Treffer aus pharmind, Nr. 10, Seite 1444 (2018))
Ready-to-use containers for sterile injectables will reduce the Total Cost of Ownership / A case study · Deutschle G, Busimi A · Schott Pharmaceutical Systems, Mainz (Germany)
The pharmaceutical industry is experiencing sweeping changes with the era of blockbuster drugs ending. The focus is shifting towards small scale personalized medicine based on biotech drugs like monoclonal antibodies (mAb), m-RNA, Antibody-Drug-Conjugates (ADCs), gene or cell therapy. Orphan drugs to treat rare diseases also demand small-scale manufacturing. Currently, more than 3 100 injectable drugs are at different stages of development globally. More than 60 % of these injectable drugs are biotech-based drugs [ 1 ]. Today, the cost of developing a new drug can exceed 2.6 billion US Dollars [ 2 ] compared to 179 million US Dollars in 1970s [ ...
